Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Chemomab Therapeutics Ltd. (ANCN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Audited Current assets Cash and cash equivalents 10,382 13,519 Short term bank deposits 16,207 26,374 Restricted cash 74 77 Other receivables and prepaid expenses 1,042 1,766 Total current assets 27,705 41,736 Non-current assets Long term prepaid expenses 646 733 Property and equipment, net 338 367 Operating lease right-of-use assets 160 227 Total non-current assets 1,144 1,327 Total assets 28,849 43,063 Current liabilities Trade payables 2,347 1,688 Accrued expenses 2,503 3,378 Employee and related expenses 1,867 1,560 Operating lease liabilities 108 123 Total current liabilities 6,825 6,749 Non-current liabilities Operating lease liabilities - long term 33 91 Total non-current liabilities 33 91 Commitments and contingent liabilities 3 Total liabilities 6,858 6,840 Shareholders'...",
"CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS",
"TEL AVIV, Israel, August 14, 2023 ─ Chemomab Therapeutics Ltd. , , a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30, 2023, and provided a corporate update. “I am pleased to report that the company continued to make good progress during the second quarter,” said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. “In June, the Board of Directors re-appointed me to the CEO position and re-appointed then Vice President of Finance Sigal Fattal as Chief Financial Officer. Our extensive prior experience in these roles and ongoing active involvement in company management have made..."
08/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
07/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Meeting”) of Chemomab Therapeutics Ltd. (the “Company",
"MAIL"
11/21/2019 6-K Quarterly results
11/15/2019 6-K Quarterly results
11/12/2019 6-K Quarterly results
10/28/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Anchiano Therapeutics Chairman Stephen Hoffmann Steps Down from Board"
09/23/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Collaboration and License Agreement, by and between Anchiano Therapeutics Inc. and ADT Pharmaceuticals, LLC",
"Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs"
08/13/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Financial Statements",
"Financial Statements"
08/06/2019 6-K Quarterly results
Docs: "FORM 6-K",
"Anchiano Therapeutics Reports Second Quarter 2019 Financial Results"
07/08/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
06/18/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Anchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange"
05/28/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Notice of the Meeting",
"Proxy Statement",
"Proxy Card"
05/22/2019 6-K Quarterly results
Docs: "FORM 6-K",
"Anchiano Therapeutics Reports First Quarter 2019 Financial Results"
03/14/2019 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Stock Exchange"
03/12/2019 6-K Quarterly results
Docs: "FORM 6-K",
"Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results"
02/14/2019 6-K Quarterly results
02/12/2019 6-K Quarterly results
12/26/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
12/17/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
11/27/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
11/14/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
11/05/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
10/22/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
10/02/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
10/01/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
09/04/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
08/20/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
08/13/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
08/09/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
07/23/2012 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy